176 related articles for article (PubMed ID: 31381630)
1. Do A-fib patients continue to benefit from vitamin K antagonists with advancing age?
Guthmann R; Bahrami A; Martin R; Nashelsky J
J Fam Pract; 2019; 68(6):E12-E14. PubMed ID: 31381630
[No Abstract] [Full Text] [Related]
2. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter.
Cairns JA; Connolly S; McMurtry S; Stephenson M; Talajic M;
Can J Cardiol; 2011; 27(1):74-90. PubMed ID: 21329865
[TBL] [Abstract][Full Text] [Related]
3. Stroke prevention in elderly patients with atrial fibrillation.
Garcia D; Hylek E
Lancet; 2007 Aug; 370(9586):460-1. PubMed ID: 17693158
[No Abstract] [Full Text] [Related]
4. Antithrombotic treatment in atrial fibrillation.
Lip GY; Boos CJ
Postgrad Med J; 2008 May; 84(991):252-8. PubMed ID: 18508982
[TBL] [Abstract][Full Text] [Related]
5. [Guidelines for antithrombotic therapy in atrial fibrillation: what the Italian Hemostasis and Thrombosis Society thinks].
Prisco D
Haematologica; 2001 Sep; 86(9 Suppl):12-3. PubMed ID: 11759618
[No Abstract] [Full Text] [Related]
6. [Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative].
Själander A; Wallentin L; Rosenqvist M; Svensson P
Lakartidningen; 2008 Sep 10-16; 105(37):2478-80. PubMed ID: 19006862
[No Abstract] [Full Text] [Related]
7. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
Hankey GJ; Klijn CJ; Eikelboom JW
Stroke; 2004 Feb; 35(2):389-91. PubMed ID: 14757889
[No Abstract] [Full Text] [Related]
8. Use of oral anticoagulants in complex clinical situations with atrial fibrillation.
Gullón A; Sánchez Fuentes D; López-de-Sá E; Martí-Almor J; Barón-Esquivias G; Jiménez López J; Del Mar Contreras Muruaga M; Suárez Fernández C
Med Clin (Barc); 2018 Jun; 150 Suppl 1():8-24. PubMed ID: 30502871
[TBL] [Abstract][Full Text] [Related]
9. Clinical inquiries. Does combining aspirin and warfarin decrease the risk of stroke for patients with nonvalvular atrial fibrillation?
Robertson SL; Mayer JB; Guthmann R
J Fam Pract; 2004 Jul; 53(7):570-5. PubMed ID: 15251100
[No Abstract] [Full Text] [Related]
10. The ten most commonly asked questions about stroke prevention in atrial fibrillation.
Halperin JL
Cardiol Rev; 2001; 9(4):187-92. PubMed ID: 11464805
[No Abstract] [Full Text] [Related]
11. Atrial fibrillation: stroke prevention in older adults.
Quinn GR; Fang MC
Clin Geriatr Med; 2012 Nov; 28(4):617-34. PubMed ID: 23101573
[TBL] [Abstract][Full Text] [Related]
12. Optimising stroke prevention in non-valvular atrial fibrillation.
Ederhy S; Cohen A
Expert Opin Pharmacother; 2006 Oct; 7(15):2079-94. PubMed ID: 17020434
[TBL] [Abstract][Full Text] [Related]
13. Summaries for patients. Rivaroxaban in patients transitioned from vitamin K antagonist therapy.
Ann Intern Med; 2013 Jun; 158(12):I-28. PubMed ID: 23778921
[No Abstract] [Full Text] [Related]
14. Prevention of stroke in patients with atrial fibrillation.
Med Lett Drugs Ther; 2009 Jun; 51(1313):41. PubMed ID: 19478692
[No Abstract] [Full Text] [Related]
15. Evidence-based emergency medicine. Anticoagulation or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter.
Diner BM
Ann Emerg Med; 2003 Jan; 41(1):141-3. PubMed ID: 12514695
[No Abstract] [Full Text] [Related]
16. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
17. Anticoagulant prevention in patients with atrial fibrillation: alternatives to vitamin K antagonists.
Kozlowski D; Budrejko S; Raczak G; Rysz J; Banach M
Curr Pharm Des; 2013; 19(21):3816-26. PubMed ID: 23286429
[TBL] [Abstract][Full Text] [Related]
18. Stroke prevention in atrial fibrillation patients.
Marinigh R; Lip GY; Lane DA
Expert Opin Pharmacother; 2010 Oct; 11(14):2331-50. PubMed ID: 20718589
[TBL] [Abstract][Full Text] [Related]
19. Methodological considerations for interpretation of rates of major haemorrhage in studies of anticoagulant therapy for atrial fibrillation.
Hylek EM; Magnani JW
Europace; 2008 Jan; 10(1):3-5. PubMed ID: 18039690
[No Abstract] [Full Text] [Related]
20. Stroke in heart failure: atrial fibrillation revisited?
Pullicino P; Homma S
J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):1-2. PubMed ID: 20123219
[No Abstract] [Full Text] [Related]
[Next] [New Search]
